Clinical Trial

A Phase II Clinical Trial of the Safety and Efficacy of SAL056 at Different Doses and Dosing Regimens

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated May 12, 2026 (before its estimated July 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a multicenter, randomized, open-label, parallel-controlled Phase II study designed to evaluate the differences in safety among four different dosing regimens of SAL056.
Trial Details
NCT Number NCT07579936
Lead Sponsor Shenzhen Salubris Pharmaceuticals Co., Ltd.
Collaborators: Salubris (Suzhou) Pharmaceutical Co., Ltd.
Conditions Postmenopausal Women With Osteoporosis
Enrollment 200 participants
Start Date 2026-04-30
Primary Completion 2026-07-30 (estimated)
Study Completion 2026-11-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-12